Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Kasturba Medical College, |
RCV001806321 | SCV002053834 | pathogenic | Glycogen storage disease, type IV | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV004040919 | SCV004874564 | uncertain significance | Inborn genetic diseases | 2024-02-20 | criteria provided, single submitter | clinical testing | The c.476C>T (p.P159L) alteration is located in exon 4 (coding exon 4) of the GBE1 gene. This alteration results from a C to T substitution at nucleotide position 476, causing the proline (P) at amino acid position 159 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of <0.001% (1/248106) total alleles studied. The highest observed frequency was 0.001% (1/112522) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |